Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colorectal cancer prevention.

Ernest T Hawk1, Bernard Levin

  • 1GI and Other Cancers Research Group, National Cancer Institute, 6130 Executive Boulevard, Suite 2141, Bethesda, MD 20892-7322, USA. eh51p@nih.gov

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|January 8, 2005
PubMed
Summary

Widespread colorectal cancer screening can improve survival rates. Early detection through effective screening methods and chemoprevention offers significant benefits for patients with colorectal neoplasia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

American Heart Association cardiovascular health metrics and cancer outcomes: A systematic review and meta-analysis.

American heart journal·2026
Same author

Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.

Journal of medicinal chemistry·2026
Same author

NCI-Designated Cancer Centers' Policies and Practices with regard to Alcohol and Cancer: A Call to Lead.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2025
Same author

Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.

Nature·2025
Same author

Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity.

Journal of medicinal chemistry·2025
Same author

Multi-cancer early detection tests: Attributes for clinical implementation.

Cancer biomarkers : section A of Disease markers·2025

Area of Science:

  • Oncology
  • Gastroenterology
  • Preventive Medicine

Background:

  • Colorectal cancer is a leading cause of mortality in the U.S., with a 6% lifetime risk and a low 5-year survival rate of 62%.
  • Late diagnosis, with only 38% of cancers localized at detection, highlights the need for improved screening strategies.
  • Current screening methods include fecal occult blood tests, sigmoidoscopy, colonoscopy, and barium enema, with new methods like virtual colonoscopy and molecular stool tests under development.

Purpose of the Study:

  • To review the current landscape of colorectal cancer screening and chemoprevention.
  • To emphasize the importance of early detection and cost-effective screening methods.
  • To discuss the role of chemopreventive compounds in reducing colorectal adenomas and cancer.

Main Methods:

Related Experiment Videos

  • Review of existing colorectal cancer screening modalities.
  • Discussion of emerging screening technologies (computed tomographic colonography, molecular stool tests).
  • Analysis of evidence for chemopreventive compounds (selenium, calcium carbonate, hormone replacement therapy, NSAIDs) in randomized trials.

Main Results:

  • Colorectal cancer screening is cost-effective regardless of the method used.
  • Four classes of chemopreventive compounds have shown efficacy in reducing adenomas and/or cancer.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) exhibit efficacy through cyclooxygenase-dependent and -independent mechanisms.

Conclusions:

  • Widespread implementation of colorectal cancer screening can significantly improve patient outcomes.
  • Chemoprevention strategies, particularly with NSAIDs, show promise but require further research on optimal dosing and toxicity profiles.
  • Minimizing toxicity is crucial when considering chemoprevention in asymptomatic individuals at low risk for colorectal neoplasia.